Posted: 11 August 2025
Cartherics Pty Ltd officially opened its new state-of-the-art cleanroom facility in Notting Hill, Victoria, marking a significant milestone in the company’s mission to advance off-the-shelf immune stem cell therapies for women’s health.
The facility was inaugurated by the Hon Ed Husic MP, Federal Member for Chifley, during a ceremony attended by industry partners and stakeholders. Cartherics confirmed that, once validated, the site would manufacture clinical batches of its lead product, CTH-401, initially for relapsed and refractory ovarian cancer. An Investigational New Drug (IND) application to the US Food and Drug Administration is planned for mid-2026.
“The completion of the cleanrooms means that clinical manufacturing can now begin for Cartherics’ therapeutic products targeting ovarian cancer and endometriosis,” said Prof Alan Trounson AO, Chief Executive Officer of Cartherics. “These advanced manufacturing facilities will provide a much-needed addition to Victoria’s translational capacity in oncology, regenerative medicine and other therapeutic applications.”
The Ferntree Place Precinct facility features advanced environmental control systems that track particle counts, airflows, air pressures, humidity, and temperature. It also houses modern manufacturing technologies, including closed processing systems, bioreactors, cleanroom-grade incubators, and a bioburden testing laboratory.
Cartherics’ research focuses on delivering innovative therapies for conditions such as ovarian cancer, triple negative breast cancer, endometriosis, and other underserved diseases. The company’s investment in this site was described as a strategic move to enhance Victoria’s biotechnology sector and reinforce Melbourne’s standing as a hub for advanced medical manufacturing and translational research.
The development of the cleanroom facility was positioned as a key enabler for scaling Cartherics’ clinical manufacturing, aligning with its broader objective to transform treatment outcomes in women’s health.
For more information click here.
